AI/ML Big Data Analysis in the largest Clinical Trial ever conducted for Antipsychotics
bfLEAP™ discovers patient-specific variables and clinical outcomes
Patients with schizophrenia are highly likely to discontinue treatment with their prescribed antipsychotic, due largely to lack of efficacy and intolerable side effects.
This is evidenced by data from various clinical studies, including the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) – the largest antipsychotics trial ever conducted. The CATIE data showed that 74% of patients discontinued before 18 months. BullFrog analyzed publicly available (de- identified) data from CATIE*, including novel pharmacokinetic and genetic data from these patients, to identify correlative relationships between individual genes and poor patient outcomes.